Stock AWH ASPIRA WOMEN'S HEALTH INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Aspira Women's Health Inc.

Equities

AWH

US04537Y2081

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-04-23 pm EDT 		5-day change 1st Jan Change
3.39 USD -3.14% Intraday chart for Aspira Women's Health Inc. -1.74% -16.91%
Apr. 01 Cantor Fitzgerald Trims Price Target on Aspira Women's Health to $3.30 From $4, Maintains Neutral Rating MT
Mar. 28 Transcript : Aspira Women's Health Inc., Q4 2023 Earnings Call, Mar 28, 2024

Business Summary

Aspira Women's Health Inc. is engaged in the discovery, development, and commercialization of noninvasive, artificial intelligence (AI)-powered tests to aid in the diagnosis of gynecologic diseases. The Company's portfolio includes OvaWatch and the Ova1Plus workflow, offered to clinicians as OvaSuite. OvaWatch is used to assess ovarian cancer risk for women with an adnexal mass where their initial clinical assessment indicates the mass is indeterminate or benign. The Ova1Plus workflow is designed to assess the risk of ovarian malignancy in women planning for surgery and uses two tests, Ova1 as the primary test and Overa as a reflex for Ova1 intermediate range results. Its in-development test pipeline includes OvaMDxSM risk assessment, EndoCheck and EndoMDx, which are designed to expand its ovarian cancer portfolio and address the tremendous need for noninvasive diagnostics for endometriosis. EndoCheck is a noninvasive test designed to identify endometriomas.

Number of employees: 64

Sales per Business

USD in Million2022Weight2023Weight Delta
Bio-analytic and Diagnostic Services
100.0 %
8 100.0 % 9 100.0 % +11.85%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
8 100.0 % 9 100.0 % +11.85%

Managers

Managers TitleAgeSince
Nicole Sandford CEO
 Chief Executive Officer 54 21-02-21
Sandra Milligan PSD
 President - Mar. 31
Torsten Hombeck DFI
 Director of Finance/CFO 54 23-06-14
April J. L. Pradier COO
 Chief Operating Officer - -
Charles J. Dunton CTO
 Chief Tech/Sci/R&D Officer - 18-09-30
Michelle Snider PRN
 Corporate Officer/Principal - 23-08-27
Minh Merchant LAW
 General Counsel 51 22-01-03
Diane Powis PRN
 Corporate Officer/Principal - 20-10-31

Members of the board

Members of the board TitleAgeSince
Ellen Vos BRD
 Director/Board Member 68 23-05-08
Stefanie Cavanaugh BRD
 Director/Board Member 58 23-05-08
Jannie Herchuk CHM
 Chairman 61 23-05-08
Winfred Parnell BRD
 Director/Board Member 71 23-05-31
Nicole Sandford CEO
 Chief Executive Officer 54 21-02-21
Celeste Fralick BRD
 Director/Board Member 68 22-02-22

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 12,344,104 7,549,381 ( 61.16 %) 0 61.16 %

Shareholders

NameEquities%Valuation
Jack Schuler
18.22 %
1,883,656 18.22 % 6 M $
Robert Drysdale
12.68 %
1,310,531 12.68 % 4 M $
H George Schuler
5.939 %
613,855 5.939 % 2 M $
Eric Schultz
5.263 %
543,998 5.263 % 2 M $
Vanguard Global Advisers LLC
1.896 %
196,007 1.896 % 607 622 $
B. Riley Wealth Advisors, Inc.
1.735 %
179,371 1.735 % 556 050 $
BlackRock Institutional Trust Co. NA
0.6072 %
62,766 0.6072 % 194 575 $
Nicole Sandford
0.5911 %
61,103 0.5911 % 189 419 $
Geode Capital Management LLC
0.5546 %
57,329 0.5546 % 177 720 $
Quantum Private Wealth LLC
0.4852 %
50,156 0.4852 % 155 484 $

Company contact information

Aspira Women's Health, Inc.

12117 Bee Caves Road Suite 100

78738, Austin

+512 519 0400

http://www.vermillion.com
address Aspira Women's Health Inc.(AWH)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Diagnostics & Testing

Ratings for Aspira Women's Health Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
3.5 USD
Average target price
3.3 USD
Spread / Average Target
-5.71%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Diagnostics & Testing

1st Jan change Capi.
ASPIRA WOMEN'S HEALTH INC. Stock Aspira Women's Health Inc.
-16.91% 43.2M
EXACT SCIENCES CORPORATION Stock Exact Sciences Corporation
-14.13% 11.33B
IOVANCE BIOTHERAPEUTICS, INC. Stock Iovance Biotherapeutics, Inc.
+45.76% 3.16B
GUARDANT HEALTH, INC. Stock Guardant Health, Inc.
-35.86% 2.14B
BGI GENOMICS CO., LTD. Stock BGI Genomics Co., Ltd.
-18.27% 2.04B
VERACYTE, INC. Stock Veracyte, Inc.
-27.92% 1.49B
MARAVAI LIFESCIENCES HOLDINGS, INC. Stock Maravai LifeSciences Holdings, Inc.
+18.02% 975M
SEEGENE, INC. Stock Seegene, Inc.
-3.49% 731M
CAREDX, INC Stock CareDx, Inc
-31.42% 423M
CURIOX BIOSYSTEMS CO., LTD Stock Curiox Biosystems Co., Ltd
+26.64% 371M
Bio Diagnostics & Testing
  1. Stock Market
  2. Equities
  3. AWH Stock
  4. Company Aspira Women's Health Inc.